The present invention relates to a novel channel structure of human amyloid beta protein (AbP) in lipid membranes and a rapid, quantitative and specific assay for screening test compounds, such as drugs, ligands (natural or synthetic), proteins, peptides and small organic molecules for their ability to bind and block the membrane AbP channels. The invention further relates to screening and identifying therapeutically relevant compounds for treating Alzheimer's disease and other disorders.